Loading...
TCMD logo

Tactile Systems Technology, Inc.NasdaqGM:TCMD Rapport sur les actions

Capitalisation boursière US$547.2m
Prix de l'action
US$24.84
US$38
34.6% sous-évalué décote intrinsèque
1Y152.2%
7D6.7%
Valeur du portefeuille
Voir

Tactile Systems Technology, Inc.

NasdaqGM:TCMD Rapport sur les actions

Capitalisation boursière : US$547.2m

Tactile Systems Technology (TCMD) Aperçu de l'action

Tactile Systems Technology, Inc. est une société de technologie médicale qui développe et fournit des dispositifs médicaux pour traiter les maladies chroniques mal desservies aux États-Unis. Plus de détails

TCMD analyse fondamentale
Score flocon de neige
Évaluation5/6
Croissance future3/6
Performances passées4/6
Santé financière6/6
Dividendes0/6

TCMD Community Fair Values

Create Narrative

See what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.

Tactile Systems Technology, Inc. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Tactile Systems Technology
Historique des cours de bourse
Prix actuel de l'actionUS$24.84
Plus haut sur 52 semainesUS$37.77
Plus bas sur 52 semainesUS$9.34
Bêta0.82
Variation sur 1 mois-2.66%
Variation sur 3 mois-12.07%
Variation sur 1 an152.18%
Variation sur 3 ans18.45%
Variation sur 5 ans-53.05%
Évolution depuis l'introduction en bourse124.19%

Nouvelles et mises à jour récentes

Mise à jour du récit Apr 23

TCMD: Lymphedema Execution And Multi Year Guidance Will Support Continued Upside

Analysts have lifted the consolidated price target for Tactile Systems Technology to around $38, supported by higher projections for revenue growth, improved profit margins, and a lower assumed future P/E multiple following recent Q4 upside and updated multi year guidance. Analyst Commentary Recent Street research on Tactile Systems Technology highlights a range of views on execution, growth prospects, and valuation following the Q4 results and updated multi year guidance.
Article d’analyse Apr 18

Should You Think About Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD) Now?

Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), might not be a large cap stock, but it received a lot of attention...
Mise à jour du récit Apr 08

TCMD: Lymphedema Momentum And Q4 Execution Will Drive Multi Year Upside

The updated analyst price target for Tactile Systems Technology has been set at $38. This reflects analysts' reactions to recent Q4 outperformance, higher long-term estimates, and ongoing attention to productivity, patient referrals, and the lymphedema business.
Mise à jour du récit Mar 25

TCMD: Lymphedema Momentum And Q4 Execution Will Support Multi Year Upside

Analysts have lifted the consolidated price target for Tactile Systems Technology to $38, reflecting a series of Street target increases into the $32 to $42 range, supported by recent Q4 outperformance, updated multi year guidance, and progress in productivity and cost controls. Analyst Commentary Street commentary around Tactile Systems Technology is mixed, with several bullish analysts lifting targets on the back of Q4 execution and longer term guidance, while more cautious voices question how much upside remains after the post earnings re rating.

Recent updates

Mise à jour du récit Apr 23

TCMD: Lymphedema Execution And Multi Year Guidance Will Support Continued Upside

Analysts have lifted the consolidated price target for Tactile Systems Technology to around $38, supported by higher projections for revenue growth, improved profit margins, and a lower assumed future P/E multiple following recent Q4 upside and updated multi year guidance. Analyst Commentary Recent Street research on Tactile Systems Technology highlights a range of views on execution, growth prospects, and valuation following the Q4 results and updated multi year guidance.
Article d’analyse Apr 18

Should You Think About Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD) Now?

Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), might not be a large cap stock, but it received a lot of attention...
Mise à jour du récit Apr 08

TCMD: Lymphedema Momentum And Q4 Execution Will Drive Multi Year Upside

The updated analyst price target for Tactile Systems Technology has been set at $38. This reflects analysts' reactions to recent Q4 outperformance, higher long-term estimates, and ongoing attention to productivity, patient referrals, and the lymphedema business.
Mise à jour du récit Mar 25

TCMD: Lymphedema Momentum And Q4 Execution Will Support Multi Year Upside

Analysts have lifted the consolidated price target for Tactile Systems Technology to $38, reflecting a series of Street target increases into the $32 to $42 range, supported by recent Q4 outperformance, updated multi year guidance, and progress in productivity and cost controls. Analyst Commentary Street commentary around Tactile Systems Technology is mixed, with several bullish analysts lifting targets on the back of Q4 execution and longer term guidance, while more cautious voices question how much upside remains after the post earnings re rating.
Mise à jour du récit Mar 09

TCMD: Lymphedema Momentum And Q4 Execution Will Support Ongoing Upside Potential

Analysts have nudged their average price target for Tactile Systems Technology to $38. This reflects stronger recent Q4 execution, raised long term estimates and ongoing improvements in productivity, patient referrals and cost controls.
Mise à jour du récit Feb 23

TCMD: Lymphedema Momentum And Q4 Execution Will Support Measured Turnaround Expectations

The analyst fair value estimate for Tactile Systems Technology has been raised from $29.75 to $38.00, reflecting higher Street price targets in the $32 to $42 range as analysts cite recent Q4 upside, improved productivity and cost controls, and ongoing strength in the lymphedema business. Analyst Commentary Street research on Tactile Systems Technology is generally constructive, with higher fair value assumptions linked to recent Q4 performance, execution on productivity and cost controls, and expectations around the lymphedema business.
Mise à jour du récit Feb 08

TCMD: Index Inclusion And Stable Outlook Will Shape Measured Turnaround Expectations

Analysts have maintained their fair value estimate for Tactile Systems Technology at $29.75 per share. They cited only very small adjustments to assumptions regarding the discount rate, revenue growth, profit margins, and future P/E multiples, rather than any change in the core outlook.
Mise à jour du récit Jan 25

TCMD: Turnaround Momentum And Buyback Will Test Q3 Outperformance Sustainability

Analysts have raised their price targets on Tactile Systems Technology to a roughly mid to high $20s to low $30s range, citing stronger than expected Q3 results, improved productivity, sales force expansion, new products, and better reimbursement trends that together support a higher fair value assessment. Analyst Commentary Recent research points to a more constructive view on Tactile Systems Technology following its Q3 outperformance, with several firms raising price targets and upgrading ratings based on execution and perceived upside to fair value.
Mise à jour du récit Jan 10

TCMD: Q3 Turnaround Momentum And Buyback Will Face Execution Risk

Analysts have raised their price target on Tactile Systems Technology to about $29.75 from $24, citing stronger recent earnings performance, expectations for operational improvements, and support for a higher future P/E multiple. Analyst Commentary Recent research updates on Tactile Systems Technology highlight a clear shift toward a more constructive stance, with multiple firms lifting price targets after Q3 results and pointing to both execution progress and valuation support.
Article d’analyse Dec 18

Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 28%

Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have continued their recent momentum with a 28% gain in the...
Mise à jour du récit Dec 17

TCMD: Q3 Outperformance And Buyback Will Mask Limited Upside Ahead

Analysts have raised their price target on Tactile Systems Technology by about $8.50 to roughly $32 per share, citing significant Q3 outperformance, improving productivity and reimbursement trends, and expectations for a return to double digit growth by 2026. Analyst Commentary Recent research updates reflect a notably more constructive stance on Tactile Systems Technology, with bullish analysts pointing to operational momentum, clearer reimbursement visibility, and a sizable underpenetrated patient pool as key drivers of potential upside in the shares.
Mise à jour du récit Dec 03

TCMD: Q3 Outperformance And Buyback Plan Will Shape Turnaround Outlook

Analysts have raised their price expectations for Tactile Systems Technology toward the low to mid $30 range, citing a massive Q3 outperformance, consistent estimate beats, and growing confidence in a 2026 growth reacceleration and higher sustainable earnings power. Analyst Commentary Recent Street research reflects a broadly constructive stance on Tactile Systems Technology following its strong Q3 performance and improving fundamentals.
Mise à jour du récit Nov 19

TCMD: Sustained Product Execution And Buyback Plan Set To Shape Outlook

Analysts have raised their price target on Tactile Systems Technology significantly, from approximately $16.83 to $24.00. They cite strong quarterly outperformance and growing confidence in the company’s turnaround and future growth prospects.
Article d’analyse Nov 06

Results: Tactile Systems Technology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) investors will be delighted, with the company turning in some strong...
Mise à jour du récit Nov 03

TCMD: Market Leadership And Coverage Momentum Will Drive Expansion Into Underserved Patients

Narrative Update on Tactile Systems Technology Analysts have reaffirmed their price target for Tactile Systems Technology at $16.83 per share. They cite the company's leadership in key market segments and anticipated growth acceleration as a result of recent strategic improvements.
Mise à jour du récit Oct 20

At-home Healthcare And Workflow Automation Will Expand Patient Reach

Analysts have maintained their price target for Tactile Systems Technology at $23.50. They cite the company's leading positions in key device markets and an improved outlook following recent strategic adjustments.
Mise à jour du récit Oct 05

At-home Healthcare And Workflow Automation Will Expand Patient Reach

Analysts have raised their fair value estimate for Tactile Systems Technology from $13.50 to $16.83 per share. The change is attributed to optimism about the company's strengthened market leadership and the potential for renewed growth following recent strategic improvements.
Article d’analyse Oct 04

When Should You Buy Tactile Systems Technology, Inc. (NASDAQ:TCMD)?

Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it saw a significant share...
Article d’analyse Aug 29

Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Shares Leap 28% Yet They're Still Not Telling The Full Story

Despite an already strong run, Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have been powering on, with a...
Article d’analyse May 12

Tactile Systems Technology's (NASDAQ:TCMD) Soft Earnings Don't Show The Whole Picture

The most recent earnings report from Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) was disappointing for...
Article d’analyse May 08

Slammed 28% Tactile Systems Technology, Inc. (NASDAQ:TCMD) Screens Well Here But There Might Be A Catch

To the annoyance of some shareholders, Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares are down a considerable...
Article d’analyse May 07

Why Tactile Systems Technology, Inc. (NASDAQ:TCMD) Could Be Worth Watching

Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it received a lot of...
Seeking Alpha Apr 07

Tactile Systems Technology: Interesting Devices Company, Need More Clarity

Summary Tactile Systems produces medical devices for lymphedema and chronic venous insufficiency, with Flexitouch Plus being the flagship product and key revenue driver. The company's products are covered by major insurers, including Medicare and Veterans Administration, serving over 275 million Americans. Financially, TCMD has a market cap of $311mn, but faces risks from increasing competition, regulatory issues, and ongoing legal matters. Despite strong revenue streams, concerns about falling EBITDA and recent revenue misses warrant a cautious approach before making investment decisions. Read the full article on Seeking Alpha
Article d’analyse Feb 23

Tactile Systems Technology (NASDAQ:TCMD) Has A Rock Solid Balance Sheet

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Article d’analyse Nov 25

Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 26%

Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have continued their recent momentum with a 26% gain in the...
Article d’analyse Nov 07

Tactile Systems Technology, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) came out with its third-quarter results last week, and we wanted to...
User avatar
Nouveau récit Sep 24

Nimbl Approval And Tech Investments Propel Growth Amid Shrinking Margins And Operational Risks

Investments in technology and workflow improvements, alongside FDA approval for Nimbl, indicate a strong focus on innovation and market expansion.
Article d’analyse Jul 17

Investors Holding Back On Tactile Systems Technology, Inc. (NASDAQ:TCMD)

With a price-to-sales (or "P/S") ratio of 1.1x Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) may be sending very...
Article d’analyse May 09

US$20.67: That's What Analysts Think Tactile Systems Technology, Inc. (NASDAQ:TCMD) Is Worth After Its Latest Results

Last week, you might have seen that Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) released its quarterly result to...
Article d’analyse Feb 23

Tactile Systems Technology, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Shareholders might have noticed that Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) filed its yearly result this time...
Article d’analyse Oct 10

Does Tactile Systems Technology (NASDAQ:TCMD) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse Sep 16

Capital Allocation Trends At Tactile Systems Technology (NASDAQ:TCMD) Aren't Ideal

What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...
Article d’analyse Jul 13

Is It Time To Consider Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD)?

Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it saw a significant share...
Article d’analyse May 10

Are Investors Undervaluing Tactile Systems Technology, Inc. (NASDAQ:TCMD) By 26%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Tactile Systems Technology fair value estimate is US$28.71...
Article d’analyse Feb 16

Is Tactile Systems Technology (NASDAQ:TCMD) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Rendement pour les actionnaires

TCMDUS Medical EquipmentUS Marché
7D6.7%4.0%-0.3%
1Y152.2%-18.6%26.7%

Rendement vs Industrie: TCMD a dépassé le secteur US Medical Equipment qui a rapporté -18.6 % au cours de l'année écoulée.

Rendement vs marché: TCMD a dépassé le marché US qui a rapporté 26.7 % au cours de l'année écoulée.

Volatilité des prix

Is TCMD's price volatile compared to industry and market?
TCMD volatility
TCMD Average Weekly Movement5.6%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Cours de l'action stable: TCMD n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de TCMD ( 6% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
19951,086Sheri Doddtactilemedical.com

Tactile Systems Technology, Inc. est une société de technologie médicale qui développe et fournit des dispositifs médicaux pour traiter les maladies chroniques mal desservies aux États-Unis. Elle propose le système Flexitouch Plus, un dispositif de compression pneumatique pour le traitement du lymphœdème, du phlébolymphœdème, du lipœdème, des insuffisances veineuses et d'autres types d'œdèmes et d'ulcères de jambe ; le système Entre Plus, un dispositif de compression pneumatique pour le traitement à domicile du lymphœdème, de l'œdème chronique, de l'insuffisance veineuse et des plaies chroniques. L'entreprise propose également Nimbl, une plateforme de compression pneumatique pour le traitement du lymphœdème des membres supérieurs ; Kylee, une application mobile pour aider les patients à s'informer sur le lymphœdème, à suivre leurs symptômes et leur traitement, ainsi qu'à partager leurs progrès avec leur médecin ; et AffloVest, un gilet portable d'oscillation à haute fréquence de la paroi thoracique pour traiter les patients souffrant de rétention de sécrétions pulmonaires résultant de la bronchectasie, de la mucoviscidose et de divers troubles neuromusculaires.

Tactile Systems Technology, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Tactile Systems Technology se comparent-ils à sa capitalisation boursière ?
TCMD statistiques fondamentales
Capitalisation boursièreUS$547.21m
Bénéfices(TTM)US$20.30m
Recettes(TTM)US$343.52m
27.6x
Ratio P/E
1.6x
Ratio P/S

Le site TCMD est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
TCMD compte de résultat (TTM)
RecettesUS$343.52m
Coût des recettesUS$81.11m
Marge bruteUS$262.41m
Autres dépensesUS$242.12m
Les revenusUS$20.30m

Derniers bénéfices déclarés

Mar 31, 2026

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)0.90
Marge brute76.39%
Marge bénéficiaire nette5.91%
Ratio dettes/capitaux propres0%

Quelles ont été les performances à long terme de TCMD?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/20 20:39
Cours de l'action en fin de journée2026/05/20 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Tactile Systems Technology, Inc. est couverte par 12 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
null nullArgus Research Company
Kyle BauserB. Riley Securities, Inc.
Anderson SchockB. Riley Securities, Inc.